Finally, emerging therapeutic strategies for targeting RET are reviewed, with a particular interest in ongoing clinical trials emphasizing the expansion of access to highly selective RET inhibitors beyond NSCLC and thyroid cancers. This evidence concerns the gene RET and non-small cell lung carcinoma.